JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265343

Human SCAF11 (SFRS2IP) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

SCAF11 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 10 and 2 bp deletion in exon 10. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

1110061H03Rik, 2610510E10Rik, AI462454, CASP-11, CTD associated SR protein 11, Renal carcinoma antigen NY REN 40, SC35 interacting protein 1, SFRS2IP, SIP-1, SRrp129, Splicing regulatory protein 129, mKIAA3013, splicing factor, arginine/serine rich 2, interacting protein

2 Images
Sanger Sequencing - Human SCAF11 (SFRS2IP) knockout HeLa cell line (AB265343)
  • Sanger seq

Unknown

Sanger Sequencing - Human SCAF11 (SFRS2IP) knockout HeLa cell line (AB265343)

Allele-1 : 2 bp deletion in exon 10.

Sanger Sequencing - Human SCAF11 (SFRS2IP) knockout HeLa cell line (AB265343)
  • Sanger seq

Unknown

Sanger Sequencing - Human SCAF11 (SFRS2IP) knockout HeLa cell line (AB265343)

Allele-2 : 1 bp deletion in exon 10.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 10 and 2 bp deletion in exon 10

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265343-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265343-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265343 Human SCAF11 (SFRS2IP) knockout HeLa cell line", "number":"AB265343-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265343-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265343-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265343 Human SCAF11 (SFRS2IP) knockout HeLa cell line", "number":"AB265343-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265343-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265343 Human SCAF11 (SFRS2IP) knockout HeLa cell line", "number":"AB265343-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265343-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265343 Human SCAF11 (SFRS2IP) knockout HeLa cell line", "number":"AB265343-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SCAF11
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SFRS2IP also known as SFRS2-interacting protein and Cisplatin Resistance-Associated Overexpressed Protein (CRISP-1) is a protein with a relative mass of around 92 kilodaltons. It primarily interacts with the serine/arginine-rich splicing factor 2 (SFRS2) as indicated by its name. Researchers have found SFRS2IP mainly in the nucleus of cells where it plays a significant role in pre-mRNA splicing. Studies show its expression in various tissues but it is especially present in actively dividing cells.
Biological function summary

Proteins like SFRS2IP contribute to the regulation of RNA processing and stability. SFRS2IP participates in the spliceosome complex facilitating correct splicing and maturation of precursor mRNA into mature RNA. This process is essential for gene expression regulation ensuring that proteins are synthesized properly and in necessary amounts. SFRS2IP's involvement in these processes influences cell cycle progression and can impact cellular responses to environmental changes.

Pathways

Several studies have included SFRS2IP in processes related to mRNA splicing and gene expression. It is closely connected to the spliceosome pathway where it cooperates with SFRS2 and other splicing factors contributing to proper intron removal and exon joining in precursor mRNA. The protein also interacts with components of the RNA transport pathway ensuring the correct delivery of mRNA to the ribosome for translation.

Scientists have linked SFRS2IP to cancer and drug resistance mechanisms. Elevated expression levels of this protein have been observed in certain neoplastic tissues suggesting a role in tumorigenesis. It is associated in pathways involving oncogenic proteins like SFRS2 which influence cell proliferation and survival. Additionally studies have highlighted a connection between this protein and cisplatin resistance where SFRS2IP may interact with DNA repair proteins to modulate the cellular response to chemotherapy.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com